Glaucoma Risk & Postmenopausal Hormone Rx

Baltimore Washington Eye Center, Maryland

Monday, February 2, 2015

Glaucoma Risk & Postmenopausal Hormone Rx


Postmenopausal hormone (PMH) therapy may be helpful in lowering the risk of glaucoma in women. According to researchers publishing in JAMA Ophthalmology taking estrogen only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG). By reviewing data from 152,163 women 50 years or older the researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG whereas each additional month of use of estrogen + progesterone or estrogen + androgen hormones did not affect risk for POAG. This is interesting information and will require further prospective clinical studies to understand fully but may offer some novel treatments for primary open angle glaucoma (POAG), an insidious sight threatening eye diseases and the most common type ofglaucoma.

If you or someone you know is concerned about the risk of glaucoma and are taking or considering taking postmenopausal hormone (PMH) therapy  you are encouraged to schedule an eye examination at Baltimore Washington Eye Center by calling 800-495-3937, visiting Baltimore Washington Eye Center or facebook.com/baltimorewashingtoneyecenter.

BaltimoreWashington Eye Center is a leading eye care practice with office locations at 200 Hospital Drive, Suite 600, Glen Burnie, Maryland 21061 and River Hill Professional Center, 6100 Day Long Lane, Suite 207, Clarksville, Maryland 21029, serving the greater Baltimore and Washington, D.C. area.